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Abstract
Background: Chance imbalance in baseline prognosis of a randomized controlled trial can lead to over or underestimation
of treatment effects, particularly in trials with small sample sizes. Our study aimed to (1) evaluate the probability of
imbalance in a binary prognostic factor (PF) between two treatment arms, (2) investigate the impact of prognostic
imbalance on the estimation of a treatment effect, and (3) examine the effect of sample size (n) in relation to the first two
objectives.
Methods: We simulated data from parallel-group trials evaluating a binary outcome by varying the risk of the outcome,
effect of the treatment, power and prevalence of the PF, and n. Logistic regression models with and without adjustment for
the PF were compared in terms of bias, standard error, coverage of confidence interval and statistical power.
Results: For a PF with a prevalence of 0.5, the probability of a difference in the frequency of the PF$5% reaches 0.42 with
125/arm. Ignoring a strong PF (relative risk=5) leads to underestimating the strength of a moderate treatment effect, and
the underestimate is independent of n when n is .50/arm. Adjusting for such PF increases statistical power. If the PF is
weak (RR=2), adjustment makes little difference in statistical inference. Conditional on a 5% imbalance of a powerful PF,
adjustment reduces the likelihood of large bias. If an absolute measure of imbalance $5% is deemed important, including
1000 patients/arm provides sufficient protection against such an imbalance. Two thousand patients/arm may provide an
adequate control against large random deviations in treatment effect estimation in the presence of a powerful PF.
Conclusions: The probability of prognostic imbalance in small trials can be substantial. Covariate adjustment improves
estimation accuracy and statistical power, and hence should be performed when strong PFs are observed.
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Introduction
Because randomization attempts to balance the distribution of
known and unknown prognostic factors (PFs) between treatment
groups, authorities view it as critical for ensuring unbiased
assessment of treatment effects [1]. Despite randomization,
imbalance in PFs as a result of chance (chance imbalance) may
still arise, and with small to moderate sample sizes such imbalance
may be substantial [2,3]. Ignoring chance imbalance in key PFs
between treatment groups may result in a biased estimate of the
treatment effect, particular when a large between-group difference
occurs in a powerful PF [4–7].
Control for unbalanced PFs is often achieved via statistical
techniques such as regression analysis, sometimes in conjunction
with other design features such as stratified randomization.
Adjusting for balanced or marginally unbalanced PFs of high
predictive value increases statistical power and reduces sample size
requirements [8–13]. While including balanced baseline covariates
in linear models does not change the estimate of treatment effect,
omitting balanced covariates in logistic regression models may lead
to underestimation of subject-specific treatment effects [14–16].
Although guidelines for RCTs recommend conducting both
unadjusted and adjusted analyses [17–19], only a minority of
trials report adjusted analyses [13,20]. Moreover, although
recommendations also suggest specifying key PFs in the protocol
based on prior judgement, there is often insufficient prior
knowledge to ascertain all important PFs before a trial commences
[13,21].
Sample size of RCTs plays a critical role in balancing known
and unknown PFs between treatment groups. Although many
clinical trials with a binary outcome employ power calculations to
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36677determine an adequate sample size, underpowered studies are
common [22–24]. Among 519 PubMed-indexed RCTs published
in December 2000, the median total sample size per trial was 52
(10
th–90
th percentile: 12–310) considering all designs and 80 (10
th–
90
th percentile: 25–369) considering only parallel-group trials [25].
A more recent systematic review of 215 two-arm parallel group
RCTS of superiority with a single primary outcome published in
six high impact factor general medical journals between January 1,
2005 and December 31, 2006 indicates a larger median total trial
size of 425 (interquartile range: 158–1041) [26]. Sample size
calculations often assume a balance of prognosis between the
treatment groups regardless of sample size, yet the distribution of
the possible unobserved PFs can be difficult to examine using
empirical data mainly because they are unobserved.
The current simulation study was designed to address three
objectives: (1) to evaluate the probability of imbalance in a binary
PF between two treatment groups in simple RCTs with standard
randomization (without stratification, blocking or minimization)
evaluating a binary outcome; (2) to investigate the impact of
prognostic imbalance on the estimation of treatment effect; and (3)
to examine the effect of sample size on the probability and impact
of prognostic imbalance in RCTs.
Methods
Simulation framework
We considered parallel group RCTs with a binary outcome in
which equal numbers of patients were randomized to the
treatment and control groups. For simplicity, we confined our
attention to only one baseline PF without stratification. Five trial
design parameters were considered: the frequency of the outcome
event in the control group; the effect of treatment on the outcome;
the strength of the association between the PF and the outcome;
the prevalence of the PF; and the sample size.
We explored two simulation settings. For setting #1, we did not
impose any level of imbalance, but simply generated a binary PF
(C=0, 1) independently from the treatment allocation (T=0, 1)
for each simulated trial. We refer to this as the ‘‘unconditional
setting’’. This setting allowed us to evaluate the cumulative
probability of prognostic imbalance greater than or equal to some
level, and address whether or not adjusting for a baseline PF that is
subject to chance imbalance improves the accuracy, precision and
efficiency of the estimation of treatment effects.
We refer to setting #2 as the ‘‘conditional setting’’ for which we
imposed a particular level of imbalance in each simulated trial,
specifically, 5% more patients in the control group having the PF
than those in the treatment group. Although, over a large number
of RCTs, the probability of repeated occurrence of imbalance
approaches zero, the conditional setting allowed us to explore
what would happen if there were a 5% imbalance in a particular
trial. This provided a way to assess the magnitude of potential bias
resulting from an imbalance if it was unobserved or omitted from
the analysis. It also allowed us to study whether this potential bias
could be controlled by increasing the sample size.
Setting #1: the unconditional setting. Each simulated
dataset in the unconditional setting consisted of a binary indicator
for treatment allocation (T=0, 1), a binary baseline PF (C=0, 1),
and a binomial response variable (Y), indicating the number of
patients who experience an outcome event (D=0, 1) for each T-C
categorization. We related the log odds of experiencing the
outcome D=1 conditional on the allocated treatment and baseline
prognosis through the following model:
Simulation model:
log
Pr(D~1DT,C)
1{Pr(D~1DT,C)
~b0zb1Tzb2C, ð1Þ
where b0 corresponds to the log odds of the outcome among
patients without the PF in the control group, b1 corresponds to the
log odds ratio (OR) of having the outcome in the experimental
treatment group relative to the control group conditional on
baseline prognosis (i.e. the treatment effect), and b2 corresponds to
the log OR of the outcome among patients having the PF versus
not conditional on treatment status.
We assumed equal numbers of patients being randomized to the
experimental group (T=1) and control group (T=0), i.e.
n1=n 0=n. We sampled C independently of T from the binomial
distribution Bin(ni, l), with prevalence l being fixed at 14 values
between 0.005 and 0.995, namely, 0.005, 0.01, 0.05, 0.1, 0.2, 0.3,
0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 0.95, and 0.995. We simulated 8
scenarios (Table 1) by varying each of three parameters to reflect
typical features of a cardiovascular prevention trial: (a) risk of
outcome event in the control group (a low risk of 0.05; and a
moderate risk of 0.10), (b) treatment effect size in the absence of
the PF (a moderate effect: relative risk [RR] of 0.75; and a zero
effect: RR of 1), and (c) effect of the PF on the outcome in the
control group (a strong effect: RR of 5; and a moderate effect: RR
of 2). If the covariates are strongly predictive of the outcome, i.e.
strong PFs, mild or moderate imbalance can result in a biased
effect estimate [3,27]. The potential impact of dissimilarity in such
strong PFs between groups can plausibly be greater when the risk
of event in the control group is low, because results of hypothesis
testing may be more sensitive to the change in the numbers of
outcome events in treatment groups when the outcomes are rare.
For each scenario, we investigated six sample sizes and the 14 l
values listed above. Considering a clinical trial aiming to detect a
moderate treatment effect (i.e. RR=0.75) and a moderate risk of
the outcome in the control group (i.e. 0.10), a standard power
calculation suggests a total of 4000 patients (2000 per group) is
needed to yield type I and type II error rates of 5% and 20%,
respectively. To assess the impact of sample size on prognostic
imbalance, we also included K, J and 1/16 of this calculated
sample size for each simulation scenario (corresponding to 1000,
500 and 125 patients per arm, respectively). We also considered
two smaller sample sizes (25 and 50 patients per arm) because
small trials occur frequently in medical publications [25]. We
simulated 10,000 trials per prevalence per sample size per
scenario.
Setting #2: the conditional setting. We also simulated
10,000 replicates for each combination of the prevalence and
sample size per scenario as per Table 1 in the conditional setting.
For each trial, 5% more patients had the PF in the control group
than the treatment group. We fixed the overall proportion of the
PF at each of the 11 values: 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7,
0.8, 0.9, and 0.95, as the probability of observing a 5% imbalance
is extremely low for l,0.05 or .0.95. We conducted all
simulations and analyses in R 2.12.1.
Analysis
Distribution of imbalance. For each scenario, we retained
the simulated proportion of patients with the PF per arm, with
continuity correction by adding 0.5 to each T-C categorization to
handle sparse cells [28]. We quantified imbalance using two
different measures: the absolute difference (D1) and the standard-
ized difference (D2), as follows:
Prognostic Imbalance in RCTs
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where p
c
i=proportion of patients having the PF (C=1) (with
continuity correction) at baseline in the treatment (i=1) or control
(i=0) group. We decided to use the absolute difference, D1, as the
primary measure of imbalance, because it is more intuitive for
clinicians. The standardized measure has been advocated for
having better statistical properties and may be more appealing to
the statistical audience [29,30]. We assessed the probabilities of
observing different levels of imbalance for each sample size: Pr
(Di$d1), where d1=0.005, 0.01, 0.025, 0.05, 0.10, 0.15, 0.20.
Impact of prognostic imbalance on treatment effect
estimation. We fit two logistic regression models to evaluate
the effect of treatment with and without adjustment for the PF.
The adjusted model was the same as the underlying simulation
model (Eq. 1) and the unadjusted model took the form of Eq. 2.
Unadjusted Model:
log
Pr(D~1DT)
1{Pr(D~1DT)
~a0za1T, ð2Þ
where a0 represents the log odds of having the outcome among
patients in the control group (with or without the PF), and a1
represents the log OR of the outcome in the experimental
treatment group relative to the control group regardless of baseline
prognosis.
For each simulated RCT, we recorded the estimated regression
coefficients, their associated estimated standard errors (SEs), 95%
confidence intervals (CIs, based on Ward test), and fitted
probabilities of the outcome for each T-C (for the adjusted model)
or C (for the unadjusted model) categorization. For each scenario,
bias of the estimated regression coefficient (^ a a1 or ^ b b1) relative to the
true log OR (b1), its empirical standard deviation (SD), and mean
squared error (MSE) were recorded for each model. The empirical
coverage of the 95% CI was computed as the proportion of CIs
that contained the true effect; and power was calculated as the
proportion of replications where the CI excluded the null.
Results
Distribution of imbalance
Figure 1 displays the cumulative probabilities of an imbalance
using the absolute measure (D1) with 25, 50, 125, 500, 1000, and
2000 patients per arm. For a fixed sample size, the probability of
imbalance varied with the prevalence of the PF (l): imbalance was
more likely to occur when l is close to 0.5, but probability
diminished as l approached 0 or 1. The probability of imbalance
increased markedly as sample size decreased regardless of l. For a
PF with prevalence of 0.5, the probability of an imbalance $5%
was about 0.02 with 1000 patients per arm, 0.1 with 500 patients
per arm, and 0.42, 0.62 and 0.67 with 125, 50 and 25 patients per
arm, respectively. When the prevalence of PF was 0.05,
Pr(D1$0.05) increased from #0.0001, 0.0004, 0.059, 0.24 and
0.29 as sample size decreased from 1000 to 25.
Figure S1 displays the cumulative probability of imbalance
using the standardized measure (D2). Because the absolute
difference was scaled by the pooled SD to create the standardized
measure, l had little impact on the probability of D2, except for
the extreme values. Common for both imbalance measures, the
chance of imbalance decreased with increasing sample size.
However, the relationship between the probability of imbalance
and the prevalence of the PF differed using different measures.
Impact of prognostic imbalance on treatment effect
estimation
Setup #1: the unconditional setting. Scenario 1 corre-
sponded to trials with a 10% risk of the outcome in the control
group, a strong prognostic factor (RR=5), and a moderate
treatment effect (RR=0.75, corresponding OR=0.73) (Table 1).
Figures 2 and 3 depict the bias and empirical SD of the point
estimator of log OR, the coverage of the 95% CI, and the
empirical statistical power for the adjusted and unadjusted models
with 125 and 2000 patients per arm. When PF was omitted from
the logistic regression, the estimated log OR was biased towards
zero.
The magnitude of bias declined as l approached 0 or 1, but
varied little with sample size when each arm had 50 or more
patients. The adjusted estimator ^ b b1 was unbiased conditional on
baseline prognosis, and independent of l and sample size, when
there were over 50 patients per arm. With 25 patients per arm,
estimated log ORs from both models tended to be biased towards
zero for l#0.1; the adjusted estimates were slightly negatively
biased for greater l values. This was possibly due to the lack of
outcome events to reliably estimate the treatment contrast (Figures
S2 and S3).
Adjusting for the PF reduced precision of the point estimator,
especially when the trial size was less than 500 per arm. The
adjusted model was able to maintain the nominal coverage of the
Table 1. Simulation scenarios for the unconditional and conditional settings.
Scenario
Effect of treatment
in RR* (B1)
Effect of PF
in RR{ (B2)
Incidence of
outcome (B0) Prevalence of PF (C) Sample size/arm
10 . 7 5 ( 20.315) 5 (2.197) 0.1 (22.197)
20 . 7 5 ( 20.315) 2 (0.811) 0.005–0.995 (a) 25
3 1 (0) 5 (2.197) (unconditional) (b) 50
4 1 (0) 2 (0.811) (c) 125
50 . 7 5 ( 20.301) 5 (1.846) 0.05 (22.944) 0.05–0.95 (d) 500
60 . 7 5 ( 20.301) 2 (0.747) (conditional) (e) 1000
7 1 (0) 5 (1.846) (f) 2000
8 1 (0) 2 (0.747)
*Relative risk of having an outcome event for people receiving the experimental treatment (vs. control treatment) without the prognostic factor.
{Relative risk of having an outcome for people with vs. without the PF in the control group.
doi:10.1371/journal.pone.0036677.t001
Prognostic Imbalance in RCTs
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e36677Figure 1. Probability of imbalance using absolute measure (D1) with different trial sizes. Lines correspond to Pr (D1$d1), where d1=0.005
(hollow circle), 0.01 (triangle), 0.025 (cross), 0.05 (X), 0.10 (diamond), 0.15 (inverted triangle), and 0.20 (filled circle), from the top to the bottom,
respectively. Top left: 25/arm, top right: 50/arm, middle left: 125/arm, middle right: 500/arm, bottom left: 1000/arm, bottom right: 2000/arm.
doi:10.1371/journal.pone.0036677.g001
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unadjusted model was less than the nominal value for most l
values, when sample size exceeded 500 per arm; the decline was
more drastic when l was near 0.5. For a PF with prevalence of 0.5,
the actual coverage of the unadjusted 95% CIs was 95%, 93.58%,
91.15%, and 88.12% with 25–125, 500, 1000 and 2000 patients
per arm, respectively.
When l decreased to 0.05, coverage of the unadjusted 95% CIs
was roughly around the nominal value. Despite a slight loss of
precision, the adjusted model had equal or greater statistical power
across of the spectrum of the prevalence of PF. The gain in power
was more marked when sample size was between 500 and 1000
per arm (Figures S4 and S5), probably due to the floor or ceiling
effect associated with very small or large sample sizes, i.e. power
from both models approached 0 or 100%, so the difference in
power between models shrank accordingly.
For a PF with prevalence of 0.5, the loss of power of the
unadjusted model relative to the adjusted model was 3.44%,
15.20%, 11.29%, 14.39%, 9.66%, and 2.61% with 25, 50, 125,
500, 1000 and 2000 patients per arm. The two models achieved
similar power for a rare PF with l,0.1. For both models, the
precision of point estimator and empirical power increased with
the number of outcome events resulted from increasing sample
size and l.
As relative risk of experiencing an outcome event for those with
the PF versus those without in the control group reduced from 5 to
2 (scenario 2), bias associated with the unadjusted point estimator
of log OR became negligible for all trial sizes (except for 25 per
arm with l#0.2). The adjusted and unadjusted models were also
similar in terms of precision, coverage of CI and statistical power
(Figures S6, S7, S8, and S9).
When the treatment had no effect on the outcome of interest
(scenarios 3 and 4), the adjusted and unadjusted models produced
unbiased point estimate despite the predictive power of the PF.
Adjusting for baseline PF was not necessary in this situation to
remove bias, and in fact it led to a slight inflation of SD. Sample
size had little impact on the comparative performance of the two
models, and nominal coverage of CI was achieved for both models
(Figure S10).
For scenarios 5–8, where there was 5% risk of the outcome in
the control group, the results demonstrated patterns similar to
those described above for the first four scenarios. Precision of the
point estimates and statistical power were lower for both models in
scenarios 5–8. The magnitude of bias of the unadjusted log OR
estimator in scenario 5 was slightly less than those in scenario 1.
Figure 2. Bias, simulation standard deviation (SD), coverage proportion and statistical power for the unadjusted and adjusted
logOR, in scenario 1, the unconditional setting, with 125 patients per arm. The unadjusted model is indicated by the dotted line with
hollow circles, and the adjusted model is indicated by the solid line with filled circles.
doi:10.1371/journal.pone.0036677.g002
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slightly with the risk of outcome event when a treatment difference
truly existed.
Figure 4 and Figures S11 and S12 display distributions of the
differences (DORR) between the estimator of OR reduction (ORR,
defined as 1 - OR) and the true ORR, i.e. DORR~O^ R RR-ORR,
across the spectrum of l, based on 10,000 trials in scenario 1, with
125 patients per arm. The vertical axis represents the proportion
of trials associated with a difference greater than or equal to a
certain value d2, where d2=0, 0.05, 0.10, 0.15, 0.2 or 0.25. While
Figure 4 corresponds to the probability of deviations in either
direction, Pr( DORR jj ƒd2), Figures S11 and S12 correspond
specifically to underestimation, Pr(DORRƒ{d2) and overestima-
tion, Pr(DORR§d2), respectively. Figure 5 and Figures S13 and
S14 present distributions of DORR for the same scenario with 2000
per arm. Tables 2 and 3 present the proportions of difference at
selected l values across all sample sizes in scenario 1.
Overall, the proportion of random deviations decreased when
the sample size, l and the size of the deviation increased. When
l=0.05 in scenario 1, the probabilities of DORR$0.05 (in either
direction) from the true ORR was 0.87–0.88 and 0.52 with 125
and 2000 patients per arm, respectively, for both models (Table 2).
In comparison, the probabilities of DORR$0.1 dropped to 0.75–
0.76 (125/arm) and 0.20 (2000/arm) at the same prevalence
(Table 3). When the treatment effect was zero, the corresponding
probabilities of a given deviation were higher (Tables 4 and 5). For
instance, probabilities of DORR$0.1 were 0.78–0.81 (125/arm) and
0.30–0.32 (2000/arm) when l=0.05 in scenario 3. The proba-
bilities of DORR$0.1 remained above 0.8 with 50 or less patients
per arm in all scenarios, when l was between 0.01 and 0.5.
In scenario 1, the distribution of the unadjusted ORR estimates
was positively skewed, indicating a higher likelihood of underes-
timation than overestimation when PF was a strong predictor of
the outcome and treatment was moderately efficacious. Adjusting
for PF made the distribution of the ORR estimator symmetric
around the true effect, i.e. random fluctuations were equally likely
in either direction. When the influence of the PF was moderate or
the actual treatment effect was zero, adjusting for PF did not
improve accuracy or precision of the estimate.
Setup #2: the conditional setting. For all 8 scenarios in the
conditional setting, the adjusted model produced roughly unbiased
estimates of the treatment effect and maintained nominal coverage
of the 95% CI. The unadjusted model overestimated treatment
effects, and the model performance was influenced by multiple
factors including the treatment effect, the effect and prevalence of
the PF, and the sample size.
Figure 3. Bias, simulation standard deviation (SD), coverage proportion and statistical power for the unadjusted and adjusted
logOR, in scenario 1, the unconditional setting, with 2000 patients per arm. The unadjusted model is indicated by the dotted line with
hollow circles, and the adjusted model is indicated by the solid line with filled circles.
doi:10.1371/journal.pone.0036677.g003
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and unadjusted models in scenario 1 under the conditional setting
with 125 and 2000 patients per arm. Ignoring the fact that 5%
more patients had this PF in the control arm led to substantial
overestimation of treatment effect. Bias was comparatively larger
when PF was rare: when l ranged between 0.05 and 0.2, bias of
the unadjusted estimate of log OR, ^ a a1, relative to b1 was between
20.18 and 20.09, with 125 per arm in scenario 1. Varying sample
size led to little change in the magnitude of bias in scenario 1,
though estimates were more variable with 125 or fewer patients
per arm. Coverage of the unadjusted CI was greater than its
nominal value with 125 or fewer per arm for most prevalence
values between 0 and 1. The coverage reduced substantially as
sample size went beyond 1000 per arm; when l#0.2 or$0.8
coverage of the unadjusted CI dropped to 60%–90%. For a fixed
sample size, the unadjusted estimate had slightly greater precision
than the adjusted estimate; but the difference diminished as sample
size increased.
With PF RR=2 in scenario 2, bias of the unadjusted point
estimator decreased with sample size and varied little with l. The
average biases of ^ a a1 over the 11 prevalence values investigated
were 20.014, 20.055 and 20.050 with 25, 50 and 125 patients
per arm respectively and reduced to 20.015, 20.007 and 20.004
when the sample size reached 500, 1000 and 2000 per arm. The
corresponding biases of the adjusted log OR estimator, ^ b b1, were
0.024, 20.024, 20.012, 20.005, 20.002 and 20.001. Both
models achieved similar coverage when sample sizes were greater
than or equal to 50 per arm, and demonstrated comparable
precision.
The unadjusted model had slightly greater power though this
advantage decreased as sample size increased. When the treatment
had no effect, performance of the adjusted and unadjusted models
in scenarios 3 and 4 was similar to that in scenario 2. Omitting a
stronger PF in analysis again led to a greater bias for a fixed
sample size and bias again shrank as trial size enlarged. Findings
similar to scenarios 1–4 were demonstrated when the risk of
Figure 4. Probability of difference between the estimated and true ORR (deviation in either direction) in scenario 1, the
unconditional setting, with 125 patients per arm. Within each graph, lines correspond to Pr (|DORR|$d2), where d2=0 (solid circle), 0.05 (bullet),
0.10 (little circle), 0.15 (square), 0.2 (diamond) and 0.25 (triangle), from top to bottom, respectively.
doi:10.1371/journal.pone.0036677.g004
Figure 5. Probability of difference between the estimated and true ORR (deviation in either direction) in scenario 1, the
unconditional setting, with 2000 patients per arm. Within each graph, lines correspond to Pr (|DORR|$d2), where d2=0 (solid circle), 0.05
(bullet), 0.10 (little circle), 0.15 (square), 0.2 (diamond) and 0.25 (triangle), from top to bottom, respectively.
doi:10.1371/journal.pone.0036677.g005
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Difference from true ORR$0.05 Unadjusted model Adjusted model
Sample size Prevalence of PF Prevalence of PF
0.01 0.05 0.1 0.2 0.5 0.01 0.05 0.1 0.2 0.5
Over- 25 0.45 0.45 0.44 0.44 0.44 0.45 0.44 0.46 0.48 0.47
estimation 50 0.46 0.44 0.43 0.42 0.39 0.47 0.47 0.47 0.47 0.45
125 0.44 0.42 0.39 0.35 0.33 0.45 0.45 0.44 0.43 0.42
500 0.37 0.33 0.29 0.24 0.20 0.38 0.38 0.37 0.36 0.33
1000 0.32 0.27 0.21 0.16 0.11 0.33 0.33 0.31 0.29 0.26
2000 0.25 0.19 0.14 0.08 0.04 0.27 0.26 0.25 0.23 0.18
Under- 25 0.52 0.50 0.48 0.47 0.51 0.52 0.51 0.48 0.46 0.46
estimation 50 0.47 0.49 0.49 0.47 0.49 0.46 0.46 0.46 0.44 0.45
125 0.43 0.45 0.46 0.48 0.48 0.43 0.43 0.43 0.43 0.41
500 0.39 0.41 0.44 0.46 0.47 0.39 0.37 0.37 0.36 0.33
1000 0.34 0.37 0.42 0.46 0.46 0.33 0.32 0.32 0.31 0.28
2000 0.28 0.33 0.38 0.44 0.44 0.27 0.26 0.26 0.25 0.20
Overall 25 0.96 0.94 0.92 0.91 0.95 0.97 0.95 0.94 0.94 0.93
50 0.93 0.92 0.92 0.89 0.88 0.93 0.93 0.93 0.91 0.90
125 0.88 0.87 0.86 0.84 0.81 0.88 0.88 0.87 0.86 0.83
500 0.76 0.75 0.73 0.70 0.66 0.76 0.75 0.74 0.72 0.67
1000 0.66 0.64 0.63 0.62 0.57 0.66 0.65 0.63 0.60 0.54
2000 0.54 0.52 0.51 0.52 0.48 0.54 0.52 0.51 0.48 0.38
ORR: odds ratio reduction; PF: prognostic factor.
doi:10.1371/journal.pone.0036677.t002
Table 3. Probability of difference between the estimated and true ORR$0.10 in the unconditional setting scenario 1.
Difference from true ORR$0.10 Unadjusted model Adjusted model
Sample size Prevalence of PF Prevalence of PF
0.01 0.05 0.1 0.2 0.5 0.01 0.05 0.1 0.2 0.5
Over- 25 0.37 0.37 0.38 0.40 0.38 0.39 0.41 0.43 0.44 0.44
estimation 50 0.40 0.39 0.39 0.38 0.33 0.42 0.43 0.43 0.43 0.39
125 0.38 0.35 0.32 0.28 0.24 0.39 0.38 0.37 0.35 0.33
500 0.26 0.22 0.17 0.12 0.08 0.27 0.25 0.24 0.22 0.18
1000 0.17 0.13 0.09 0.05 0.02 0.18 0.18 0.16 0.14 0.09
2000 0.09 0.05 0.03 0.01 0.00 0.10 0.09 0.07 0.07 0.03
Under- 25 0.51 0.49 0.47 0.43 0.42 0.52 0.49 0.46 0.43 0.42
estimation 50 0.41 0.43 0.44 0.45 0.42 0.41 0.43 0.42 0.40 0.40
125 0.39 0.40 0.41 0.42 0.39 0.38 0.38 0.38 0.37 0.34
500 0.29 0.30 0.31 0.32 0.30 0.28 0.27 0.26 0.24 0.20
1000 0.21 0.23 0.25 0.26 0.24 0.20 0.20 0.19 0.17 0.13
2000 0.13 0.15 0.17 0.19 0.15 0.12 0.11 0.10 0.08 0.05
Overall 25 0.88 0.86 0.85 0.83 0.80 0.91 0.90 0.89 0.88 0.86
50 0.81 0.81 0.83 0.82 0.75 0.83 0.85 0.85 0.83 0.79
125 0.76 0.75 0.72 0.70 0.63 0.76 0.76 0.75 0.72 0.67
500 0.55 0.52 0.49 0.45 0.38 0.55 0.52 0.50 0.47 0.39
1000 0.38 0.36 0.34 0.32 0.26 0.38 0.37 0.35 0.30 0.22
2000 0.22 0.20 0.20 0.20 0.15 0.22 0.20 0.18 0.15 0.08
ORR: odds ratio reduction; PF: prognostic factor.
doi:10.1371/journal.pone.0036677.t003
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Difference from true ORR$0.05 Unadjusted model Adjusted model
Sample size Prevalence of PF Prevalence of PF
0.01 0.05 0.1 0.2 0.5 0.01 0.05 0.1 0.2 0.5
Over- 25 0.39 0.41 0.41 0.42 0.43 0.39 0.44 0.47 0.48 0.47
estimation 50 0.44 0.44 0.44 0.45 0.46 0.44 0.47 0.47 0.47 0.46
125 0.45 0.46 0.46 0.45 0.42 0.46 0.45 0.45 0.45 0.44
500 0.41 0.41 0.39 0.39 0.36 0.33 0.32 0.31 0.30 0.27
1000 0.36 0.35 0.35 0.33 0.31 0.37 0.36 0.36 0.35 0.32
2000 0.31 0.30 0.29 0.27 0.23 0.31 0.30 0.30 0.29 0.26
Under- 25 0.40 0.41 0.41 0.43 0.44 0.41 0.45 0.47 0.47 0.48
estimation 50 0.43 0.43 0.45 0.45 0.45 0.43 0.46 0.47 0.47 0.46
125 0.46 0.46 0.46 0.45 0.42 0.46 0.45 0.45 0.44 0.44
500 0.40 0.40 0.39 0.38 0.35 0.41 0.40 0.40 0.39 0.37
1000 0.37 0.36 0.35 0.34 0.31 0.37 0.37 0.35 0.35 0.33
2000 0.32 0.31 0.30 0.28 0.24 0.32 0.32 0.31 0.29 0.26
Overall 25 0.79 0.81 0.82 0.85 0.87 0.80 0.89 0.93 0.95 0.95
50 0.86 0.88 0.89 0.90 0.91 0.87 0.93 0.94 0.94 0.92
125 0.92 0.93 0.92 0.91 0.83 0.92 0.90 0.90 0.89 0.88
500 0.81 0.81 0.78 0.77 0.71 0.73 0.72 0.71 0.69 0.64
1000 0.73 0.71 0.70 0.67 0.61 0.73 0.73 0.72 0.70 0.65
2000 0.63 0.60 0.59 0.55 0.47 0.63 0.62 0.61 0.58 0.53
ORR: odds ratio reduction; PF: prognostic factor.
doi:10.1371/journal.pone.0036677.t004
Table 5. Probability of difference between the estimated and true ORR$0.10 in the unconditional setting scenario 3.
Difference from true ORR$0.10 Unadjusted model Adjusted model
Sample size Prevalence of PF Prevalence of PF
0.01 0.05 0.1 0.2 0.5 0.01 0.05 0.1 0.2 0.5
Over- 25 0.39 0.41 0.41 0.42 0.43 0.39 0.42 0.45 0.46 0.44
estimation 50 0.44 0.44 0.44 0.45 0.39 0.43 0.44 0.44 0.43 0.42
125 0.38 0.39 0.39 0.38 0.36 0.39 0.40 0.39 0.39 0.37
500 0.31 0.30 0.28 0.27 0.23 0.31 0.31 0.29 0.29 0.25
1000 0.24 0.22 0.21 0.18 0.14 0.24 0.23 0.22 0.21 0.16
2000 0.16 0.14 0.13 0.11 0.06 0.16 0.14 0.14 0.12 0.09
Under- 25 0.40 0.41 0.41 0.43 0.44 0.40 0.43 0.45 0.45 0.46
estimation 50 0.43 0.43 0.45 0.45 0.41 0.43 0.43 0.45 0.44 0.42
125 0.41 0.39 0.39 0.39 0.37 0.42 0.41 0.40 0.39 0.38
500 0.32 0.31 0.30 0.28 0.24 0.33 0.32 0.31 0.30 0.27
1000 0.26 0.25 0.22 0.20 0.16 0.26 0.26 0.24 0.22 0.20
2000 0.18 0.17 0.15 0.12 0.08 0.18 0.17 0.17 0.15 0.11
Overall 25 0.79 0.81 0.82 0.85 0.87 0.79 0.84 0.89 0.91 0.89
50 0.86 0.88 0.89 0.89 0.80 0.86 0.88 0.88 0.87 0.84
125 0.79 0.78 0.78 0.78 0.73 0.81 0.81 0.80 0.78 0.75
500 0.63 0.61 0.58 0.54 0.47 0.64 0.63 0.60 0.59 0.52
1000 0.49 0.47 0.43 0.38 0.30 0.50 0.49 0.47 0.43 0.36
2000 0.34 0.30 0.27 0.23 0.15 0.34 0.32 0.30 0.27 0.20
ORR: odds ratio reduction; PF: prognostic factor.
doi:10.1371/journal.pone.0036677.t005
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(scenarios 5–8). A low event rate in each trial resulted in reduced
precision and statistical power. Bias of the unadjusted log OR
estimates decreased with sample size and was generally smaller
than the counterpart in the previous scenarios.
Discussion
Our simulation results demonstrate that small sample size is
associated with a high risk of imbalance in PFs in individual simple
RCTs. The probabilities of an absolute imbalance $5% in a
binary PF of prevalence 0.5 is 0.42, 0.62 and 0.67 with 125, 50
and 25 patients per arm. The probability of absolute imbalance
decreases as sample size increases or prevalence of PF approaches
0o r1 .
Failing to adjust for a largely balanced strong PF (RR=5) in a
logistic regression model leads to bias toward no treatment effect
when the actual size of treatment effect is moderate (RR=0.75);
this bias varies little with sample size greater than 50 patients per
arm. Adjusting for such a PF reduces precision of the effect
estimate but increases statistical power. The gain in power is
comparatively larger when sample size is between 500 and 1000
per arm and prevalence is within 0.2–0.6, relative to other cases.
When the PF is less powerful and a treatment difference exists,
improvement in accuracy and efficiency associated with the
adjustment for a largely balanced PF is less noticeable. When the
treatment effect is zero, such covariate adjustment leads to
minimal loss of precision. Overall the simulation results based
on a single binary baseline PF suggest it is critical to adjust for
important PFs in trials evaluating a binary outcome. If ignored,
substantial bias due to confounding or non-collapsibility can
emerge; bias would be more marked when PF has high predictive
value and sample size is small to moderate.
It is challenging to establish a single rule for sample size
requirement focused on the probability and impact of prognostic
imbalance. Multiple factors influence the requirement.
Firstly, sample size should be sufficiently large that the
probability of imbalance is restricted to a reasonably low value.
The adequate sample size varies with the choice of imbalance
measure, the size of imbalance that is deemed important, and the
prevalence of the PF. For example, Figure 1 suggests that if an
absolute measure of imbalance $0.05 is deemed important, 1000
patients per arm is a reasonable size.
Secondly, sample size should be sufficient to produce a reliable
estimate of treatment effect. Although it has less impact on the
magnitude of bias around the mean effect estimate in the
unconditional setting, sample size does affect precision. While
adjusting for PF removes systematic bias, estimates from an
individual trial may still deviate from the true effect in either
direction due to random sampling variation. Tables 2 and 4
suggest that probabilities of having an absolute deviation .=0.05
(in either direction) from the true ORR are 0.87–0.93 and 0.52–
0.62 for trials recruiting 125 and 2000 patients per arm,
respectively. If trialists are willing to tolerate a slightly bigger
deviation from the true ORR, for instance, no more than 0.1, the
above probabilities decrease to 0.75–0.81 (125/arm) and 0.20–
0.32 (2000/arm) for both models, and 2000 patients per arm then
seems to be a reasonable sample size (Tables 3 and 5). As PF
becomes less prevalent, larger trial sizes are required for purposes
of precision. When randomization partially or completely fails, no
statistical adjustment or increase in sample size can fully correct
the resulting bias.
The current investigation on the likelihood of prognostic
imbalance and its implications for sample size requirements is
consistent with previous findings. A minimum of 100 patients per
arm has been suggested to control the chance of imbalance of 20%
or more in a single PF [31], and 1350 per arm may be needed to
minimize the chance of a 5% imbalance [3]. Although Cui et al
calculated the probabilities of a 20% imbalance in at least one out
of k independent PFs (k=2, 3, and 4) [31], situations involving
multiple correlated PFs are worth further investigation.
Gail first demonstrated that omitting balanced baseline
covariates in logistic regression asymptotically (i.e. for very large
sample sizes) results in downward bias on the subject-specific
treatment-outcome association [14]. This is also referred to as the
non-collapsibility problem [16], because the odds ratio as the
measure of association between the treatment and the binary
outcome within each category of the baseline covariates (i.e.
conditional or subject-specific association) is different from the
association across all categories of the covariates (i.e. the marginal
or average association).
In their simulation study [32], Negassa and Hanley showed that
omitting an important balanced continuous or binary covariate in
logistic regression model lowers both the coverage probability (that
is, the proportion of the time that the CI contains the true value of
interest in a set of hypothetical repetition of data collection and
analysis procedure [33]) and study power in binary trials with
moderate sample sizes (n=500 and 1000). These findings are
complemented by a simulation study that explored the effect of
imbalance in two continuous baseline covariates on power in a
logistic regression framework when both variables were adjusted
for in analyzing small trials (n=50, 100 and 300) [12]. Others
quantified the increase in statistical power resulting from covariate
adjustment as a decrease in the sample size required in comparison
to the unadjusted model [11].
It was not clear in the literature, however, how the interplay of
chance imbalance, the risk of outcome and the prevalence of a
binary PF affects treatment effect estimation in trials with a binary
outcome. Our simulation study provided information on what
constitute an adequate sample size to control against potential
impact of prognostic imbalance. Our results based on trials subject
to chance imbalance across six sample sizes in the unconditional
setting are consistent with the previous findings.
When one is confident that all important PFs are distributed
similarly between treatment groups in a binary trial, it is sensible to
decide if the goal of a trial evaluating a binary outcome is to assess
the marginal effect of treatment over patients with heterogeneous
baseline prognosis, or to obtain a more individualized treatment
effect estimate that is specific to a prognosis. These objectives can
be achieved by using the unadjusted and adjusted logistic
regression analyses. With a binary outcome, the two models
produce mathematically different results in the presence of a non-
zero treatment effect. Mismatch of the study objective, the
statistical method, and interpretation of results can result in
misleading messages. Due to the uncertainty around the existence
or magnitude of the treatment effect and possibly different criteria
to assess prognostic imbalance, we recommend reporting both the
adjusted and unadjusted results in the manuscript.
The CPMP guideline recommends that including important
PFs in the primary analysis can be justified only if their
associations with the primary outcome are expected to be strong,
based on previous evidence, and are specified a priori [18]. What
constitutes adequate justification may be a matter of judgment.
Our results demonstrate the value of adjustment, and suggest the
merits of avoiding excessively stringent criteria when deciding
whether prior evidence of prognostic power is adequate.
Our study has several limitations. First, we included only one
binary baseline PF to illustrate the probability and impact of
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continuous PFs, Ciolino and colleagues proposed a rank-sum ratio
to measure the level of imbalance in addition to the commonly
used mean values [12]. When multiple PFs are present at baseline,
balancing distribution of the individual PFs and the overall
prognosis needs to be assessed. Although the single binary PF
considered in the current study can be conceptualized as a
measure of the overall prognosis of a patient based on multiple
PFs, for instance, in a propensity score framework [34], further
investigation on the distribution and impact of multiple correlated
PFs on effect estimation in RCTs is warranted.
Second, although our investigation was focused on prognostic
balancing in individual RCTs, systematic reviews and meta-
analyses face the same methodological challenges. The cumulative
number of patients from individual RCTs and the between-study
variation need to be considered to assess the impact of imbalance
on obtaining an aggregated estimate of treatment effects. Future
work is needed in these directions.
Our study provides useful new insights. The results can not only
help to design clinical trials, but can also inform quality assessment
of a body of evidence from RCTs. Our simulation findings provide
insights on prognostic imbalance which pertains to both risk of
bias and imprecision [35]. The current study was not designed to
propose a single threshold value of sample size that can be readily
employed to rate the quality of evidence with respect to precision.
Rather it lends itself to guide selection of such threshold values
over various combinations of trial parameters, a subjective process
likely influenced by the tolerance of risk.
In summary, prognostic imbalance does not on average
jeopardize internal validity of findings from RCTs, but if
neglected, may lead to chance confounding and biased estimate
of treatment effect in a single RCT. To produce an accurate
estimate of the treatment-outcome relationship conditional on
patients’ baseline prognosis, balanced or unbalanced PFs with high
predictive value should be adjusted for in the analysis. Covariate
adjustment slightly reduces precision, but improves study efficien-
cy, when PFs are largely balanced. Once chance imbalance in
baseline prognosis is observed, covariate adjustment should be
performed to remove chance confounding.
Supporting Information
Figure S1 Probability of imbalance using standardized
measure (D2) with different trial sizes. Lines correspond to
Pr (D2$d1), where d1=0.005 (hollow circle), 0.01 (triangle), 0.025
(cross), 0.05 (X), 0.10 (diamond), 0.15 (inverted triangle), and 0.20
(filled circle), from the top to the bottom, respectively. Top left:
25/arm, top right: 50/arm, middle left: 125/arm, middle right:
500/arm, bottom left: 1000/arm, bottom right: 2000/arm.
(TIF)
Figure S2 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 1, the
unconditional setting, with 25 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S3 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 1, the
unconditional setting, with 50 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S4 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 1, the
unconditional setting, with 500 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S5 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 1, the
unconditional setting, with 1000 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S6 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 2, the
unconditional setting, with 25 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by solid line with filled
circles.
(TIF)
Figure S7 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 2, the
unconditional setting, with 50 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S8 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 2, the
unconditional setting, with 125 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by solid line with filled
circles.
(TIF)
Figure S9 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 2, the
unconditional setting, with 2000 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S10 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 3, the
unconditional setting, with 125 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
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PLoS ONE | www.plosone.org 11 May 2012 | Volume 7 | Issue 5 | e36677Figure S11 Probability of difference between the esti-
mated and true ORR (underestimation) in scenario 1,
the unconditional setting, with 125 patients per arm.
Within each graph, lines correspond to Pr (DORR#2d2), where
d2=0 (solid circle), 0.05 (bullet), 0.10 (little circle), 0.15 (square),
0.2 (diamond) and 0.25 (triangle), from top to bottom, respectively.
(TIF)
Figure S12 Probability of difference between the esti-
mated and true ORR (overestimation) in scenario 1, the
unconditional setting, with 125 patients per arm. Within
each graph, lines correspond to Pr (DORR$d2), where d2=0 (solid
circle), 0.05 (bullet), 0.10 (little circle), 0.15 (square), 0.2 (diamond)
and 0.25 (triangle), from top to bottom, respectively.
(TIF)
Figure S13 Probability of difference between the esti-
mated and true ORR (underestimation) in scenario 1,
the unconditional setting, with 2000 patients per arm.
Within each graph, lines correspond to Pr (DORR#2d2), where
d2=0 (solid circle), 0.05 (bullet), 0.10 (little circle), 0.15 (square),
0.2 (diamond) and 0.25 (triangle), from top to bottom, respectively.
(TIF)
Figure S14 Probability of difference between the esti-
mated and true ORR (overestimation) in scenario 1, the
unconditional setting, with 2000 patients per arm. Within
each graph, lines correspond to Pr (DORR$d2), where d2=0 (solid
circle), 0.05 (bullet), 0.10 (little circle), 0.15 (square), 0.2 (diamond)
and 0.25 (triangle), from top to bottom, respectively.
(TIF)
Figure S15 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 1, the
conditional setting, with 125 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
Figure S16 Bias, simulation standard deviation (SD),
coverage proportion and statistical power for the
unadjusted and adjusted logOR, in scenario 1, the
conditional setting, with 2000 patients per arm. The
unadjusted model is indicated by the dotted line with hollow
circles, and the adjusted model is indicated by the solid line with
filled circles.
(TIF)
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